RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
  Anorexia Nervosa
  Anxiety
  Bulimia
  CFS
  Child Psychiatry
  Depression
  Forensic Psychiatry
  Learning-Disabilities
  Mood Disorders
  Neuropsychiatry
  Peri-Natal Psychiatry
  Personality Disorders
  Psychology
  Psychoses
  Psychotherapy
  Sleep Disorders
  Substance Abuse
  Suicide
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Sep 15, 2017 - 4:49:58 AM
Systematic Review
RAND Corporation study
Psychiatry Channel

subscribe to Psychiatry newsletter
Latest Research : Psychiatry

   EMAIL   |   PRINT
New Systematic Review on Efficacy and Safety of Second Generation Antipsychotics (SGAs) for Off-Label Uses

Oct 1, 2011 - 11:00:00 PM , Reviewed by: Dr. Himanshu Tyagi

Evidence supports the effectiveness of some atypical antipsychotics in reducing symptoms of generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder and behavioural symptoms in elderly patients with dementia, although significant side effects were noted.


Level of Evidence
1a - Systematic Review of Randomised Control Trails
Key Points of this article
The RAND analysis did not find evidence to support the efficacy of atypical antipsychotic medications for substance abuse, eating disorders or insomnia.
Risperidone is associated with improvement in symptoms of obsessive compulsive disorder among those who have not responded sufficiently to standard therapy
Risperidone also can improve symptoms of post-traumatic stress disorder among those who have not responded to standard drugs
Atypical antipsychotics were associated with side effects, including a small but significant increased risk of death among elderly patients with dementia.
 
[RxPG] Medical evidence suggests that psychiatric drugs known as atypical antipsychotics are effective in reducing symptoms for some off-label conditions, but not others, according to a new RAND Corporation study.

Evidence supports the effectiveness of some atypical antipsychotics in reducing symptoms of generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder and behavioural symptoms in elderly patients with dementia, although significant side effects were noted.

Researchers found insufficient evidence to support efficacy of the medications for treating eating disorders, substance abuse and insomnia. The findings are published in the Sept. 28 edition of the Journal of the American Medical Association.

"The use of atypical antipsychotic medications has spread rapidly beyond the illnesses they originally were developed to treat," said lead author Dr. Alicia Ruelaz Maher, a psychiatrist and researcher at RAND, a non-profit research organization. "While evidence suggests the drugs help reduce symptoms for some off-label illnesses, we found a lack evidence for others."

Atypical antipsychotic medications are approved for marketing and labelling by the U.S. Food and Drug Administration to treat schizophrenia, bipolar disorders and depression under drug-specific circumstances.

Use of atypical antipsychotic medications has grown rapidly, with one study estimating that treatment visits for the drugs increased from 6.2 million in 1995 to 14.3 million in 2008. Use of these drugs for off-label indications -- uses not approved by the U.S. Food and Drug Administration -- doubled during the same period.

While prescription medications frequently are prescribed for illnesses prior to approval by the FDA, concerns have been raised about the practice with atypical antipsychotics because they have substantial side effects.

Researchers from the RAND-based Southern California Evidence-Based Practice Center conducted an extensive review of the medical literature to find studies that examined the safety and effectiveness of atypical antipsychotics for off-label uses.

They identified 162 clinical trials that involved one or more of the nine atypical antipsychotic medications approved by the FDA, as well as 231 large observational studies that followed patients being prescribed one of the medications. Relevant studies published in the English language were identified by searches of 6 databases (PubMed, EMBASE, CINAHL, PsycInfo, Cochrane DARE, and CENTRAL) from inception through May 2011. Observational studies with sample sizes of greater than 1000 patients were included to assess adverse events.

The review found that aripiprazole, olanzapine and risperidone are associated with small, but significant benefits with the treatment of behavioural symptoms in dementia. Drug dosage generally was about half of that needed in treating adults with schizophrenia or bipolar disorder.

Three large trials of quetiapine reported a modest benefit for treatment of generalized anxiety disorder. The review found risperidone is associated with improvement in symptoms of obsessive compulsive disorder among those who have not responded sufficiently to standard therapy. Risperidone also can improve symptoms of post-traumatic stress disorder among those who have not responded to standard drugs.

Atypical antipsychotics were associated with side effects, including a small but significant increased risk of death among elderly patients with dementia. Other risks in the elderly included cardiovascular problems, movement disorders and urinary tract infections. Side effects in younger patients included weight gain, fatigue and sedation.

"Because these medications pose the risk of serious side effects, I would hope they would be prescribed for these off-label illnesses only in the most-serious cases and for those patients who have not responded to other drugs," Maher said. "But use of atypical antipsychotic medications has grown so fast that we can't be sure that is the case."

The RAND analysis did not find evidence to support the efficacy of atypical antipsychotic medications for substance abuse, eating disorders or insomnia.

"This type of review is designed to help clinicians, patients and families better understand whether there is evidence regarding medications for off-label uses," said Margaret Maglione, a study co-author and a RAND policy analyst. "These findings will help physicians and families better weigh benefits and possible harms of using atypical antipsychotic medications off-label."


Original research article: http://jama.ama-assn.org/content/306/12/1359.full.pdf+html 
Publication: Maher AR et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults. JAMA 2011 Sep 28; 306:1359.
On the web: Journal of the American Medical Association 

Funding information and declaration of competing interests: Support for the study was provided by the U.S. Agency for Healthcare Research and Quality.
Related Psychiatry News
Crystal methamphetamine use by street youth increases risk of injecting drugs
Drivers who test positive for drugs have triple the risk of a fatal car crash
Sex trafficking and exploitation of minors serious problems in the US, says new report
Study reveals why warnings may be ineffective at teaching young people about risks
The skinny on cocaine
82 percent of adults support banning smoking when kids are in the car
New evidence suggests impulsive adolescents more likely to drink heavily
Missing enzyme linked to drug addiction
Addiction to unhealthy foods could help explain the global obesity epidemic
Older people may be at greater risk for alcohol impairment than teens, according to Baylor Study

Subscribe to Psychiatry Newsletter

Enter your email address:


 About Dr. Himanshu Tyagi
This news story has been reviewed by Dr. Himanshu Tyagi before its publication on RxPG News website. Dr. Himanshu Tyagi, MBBS MRCPsych is the founder editor and manager for RxPG News. In this position he is responsible for content development and overall website and editorial management functions. His areas of special interest are psychological therapies and evidence based journalism. He can be reached for corrections and feedback at [email protected]
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
 Additional information about the news article
Other authors of the study are Dr. Steven Bagley of the VAs Palo Alto Healthcare System, Marika Suttorp, Jian-Hui Hu, Brett Ewing, Zhen Wang and Martha Timmer of RAND, Dr. David Sultzer of the West Los Angeles VA Medical Center and UCLA, and Dr. Paul Shekelle of RAND and the West Los Angeles VA Medical Center.

RAND Health, a division of the RAND Corporation, is USA's largest independent health policy research program, with a broad research portfolio that focuses on health care costs, quality and public health preparedness, among other topics.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

Online ACLS Certification

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)